🔴 Kailera Therapeutics is trading 4% down today as side effect concerns weigh on Phase 3 GLP-1 data

Kailera Therapeutics is trading 4% down at $20.16 as investors reassess last week’s Phase 3 data for its oral GLP-1 agonist, KAI-7535.

• While the stock initially rose on positive topline results, concerns regarding high rates of nausea and vomiting in trials are now weighing on sentiment.
• The focus on these tolerability issues is driving follow-through weakness following the initial data release.